Wazir Kashmala, Abubakar Muhammad, Anwar Ayisha, Rahat Rashid Farah, Adil Afshan, Sajjad Muhammad
Medicine, Lady Reading Hospital Peshawar, Peshawar, PAK.
Internal Medicine Residency Program, Medical Education, Hamad General Hospital, Doha, QAT.
Cureus. 2025 Mar 28;17(3):e81386. doi: 10.7759/cureus.81386. eCollection 2025 Mar.
Background Despite improvements in medical treatment, sepsis remains a deadly illness with high fatality rates that is characterized by excessive inflammation and oxidative stress. Objective This study aimed to evaluate the impact of vitamin C supplementation on inflammatory response, oxidative stress, and clinical outcomes in sepsis patients. Methodology A prospective observational study was conducted over one year at Lady Reading Hospital, Peshawar, including 326 adult sepsis cases meeting the Sepsis-3 criteria. To maximize early therapeutic benefits, intravenous vitamin C supplementation (1,500 mg/day) was administered for 14 days, followed by a maintenance regimen of 1,500 mg/day for 14 days every 3-6 months to sustain therapeutic effects. The efficacy of vitamin C was assessed through serial measurements of oxidative stress markers (malondialdehyde) and inflammatory markers (CRP, IL-6, and TNF-α) at baseline and at 3, 6, 9, and 12 months. Clinical outcomes, including ICU stay, organ dysfunction, and mortality, were prospectively recorded. Statistical analysis was performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Results Vitamin C supplementation in sepsis patients led to significant improvements over 12 months, with reductions in IL-6 (345.16 ± 128.52 to 245.12 ± 83.78 pg/mL), C-reactive protein (CRP) (175.31 ± 62.43 to 114.57 ± 38.67 mg/L), and malondialdehyde (MDA) levels (8.94 ± 3.21 to 5.79 ± 2.18 nmol/mL). Clinical outcomes also improved, including a decrease in the 30-day mortality rate from 14.11% (n=46) to 6.90% (n=22), organ dysfunction score from 9.82 ± 4.03 to 4.83 ± 2.54, and ICU stay from 11.57 ± 3.85 to 7.24 ± 3.01 days. Regression analysis indicated that vitamin C supplementation was significantly associated with better outcomes (β = -2.34, p = 0.012), while chronic kidney disease was associated with worse outcomes (β = 1.75, p < 0.001). Conclusion Supplementing with vitamin C has been shown to significantly improve clinical outcomes in sepsis by lowering oxidative stress and inflammation.
尽管医学治疗有所改善,但脓毒症仍然是一种死亡率很高的致命疾病,其特征是过度炎症反应和氧化应激。
本研究旨在评估补充维生素C对脓毒症患者炎症反应、氧化应激及临床结局的影响。
在白沙瓦的雷丁夫人医院进行了一项为期一年的前瞻性观察性研究,纳入326例符合脓毒症-3标准的成年脓毒症病例。为了最大化早期治疗益处,静脉补充维生素C(1500毫克/天)持续14天,随后每3至6个月维持1500毫克/天的方案持续14天以维持治疗效果。通过在基线以及第3、6、9和12个月连续测量氧化应激标志物(丙二醛)和炎症标志物(CRP、IL-6和TNF-α)来评估维生素C的疗效。前瞻性记录临床结局,包括重症监护病房(ICU)住院时间、器官功能障碍和死亡率。使用SPSS 25版(美国纽约州阿蒙克市IBM公司)进行统计分析。
脓毒症患者补充维生素C在12个月内带来了显著改善,IL-6水平从345.16±128.52降至245.12±83.78皮克/毫升,C反应蛋白(CRP)从175.31±62.43降至114.57±38.67毫克/升,丙二醛(MDA)水平从8.94±3.21降至5.79±2.18纳摩尔/毫升。临床结局也得到改善,包括30天死亡率从14.11%(n = 46)降至6.90%(n = 22),器官功能障碍评分从9.82±4.03降至4.83±2.54,ICU住院时间从11.57±3.85天降至7.24±3.01天。回归分析表明补充维生素C与更好的结局显著相关(β = -2.34,p = 0.012),而慢性肾病与更差的结局相关(β = 1.75,p < 0.001)。
已证明补充维生素C可通过降低氧化应激和炎症显著改善脓毒症的临床结局。